Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

Stock Information for IRIDEX Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IRIDEX Corporation

Iridex Comments on Recent Stock Price Volatility
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024
Iridex Comments on Changing Glaucoma Reimbursement Landscape
Iridex Reports Third Quarter 2024 Financial Results
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
Iridex Appoints Patrick Mercer as Chief Executive Officer
Iridex Reports Second Quarter 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.